ABSTRACT
Since late April 2020, data regarding Kawasaki-like syndrome and hyperinflammatory response in children associated with COVID-19 has rapidly emerged. Much remains unknown about the risk factors, pathogenesis, prognosis, and specific therapy for this emerging manifestation of COVID-19 known as Multisystem Inflammatory Syndrome in Children (MIS-C). MIS-C is rare and early recognition is crucial though no standardized treatment guideline have been established. Worldwide collaboration will be important as more cases are recognized going forward.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Sirada Panupattanapong, MD
- Elizabeth B. Brooks, MD, PhD
ABSTRACT
Since late April 2020, data regarding Kawasaki-like syndrome and hyperinflammatory response in children associated with COVID-19 has rapidly emerged. Much remains unknown about the risk factors, pathogenesis, prognosis, and specific therapy for this emerging manifestation of COVID-19 known as Multisystem Inflammatory Syndrome in Children (MIS-C). MIS-C is rare and early recognition is crucial though no standardized treatment guideline have been established. Worldwide collaboration will be important as more cases are recognized going forward.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
Registration is Now Required for Free Access to CCJM Content
Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.
If you are using a mobile device, click on the settings icon to access the Register link.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.